在地幔细胞淋巴瘤的前线治疗中,趋同的方法
1Siteman Cancer Center, Washington University in St Louis School of Medicine, St Louis, Missouri.
Clinical advances in hematology & oncology : H&O
|November 14, 2025
概括
布鲁顿氨酸激酶抑制剂 (BTKis) 改善了地幔细胞淋巴瘤,一种罕见的非霍奇金淋巴瘤的结果. 对于TP53突变的疾病,非化疗选择是首选的.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 薄膜细胞淋巴瘤 (MCL) 是一种异质的非霍奇金淋巴瘤,主要影响老年人.
- 目前的疗法提供有限的治愈率,需要新的治疗策略.
- 布鲁顿氨酸激酶抑制剂 (BTKis) 在准MCL的遗传脆弱性方面表现有前途.
研究的目的:
- 审查在上衣细胞淋巴瘤中BTKis的临床数据.
- 评估BTKis的整合到新诊断的MCL的第一线治疗中.
- 讨论TP53突变的MCL的治疗考虑因素.
主要方法:
- 审查临床试验数据和科学文献.
- 分析BTKi的疗效和安全性概况.
- 基于遗传突变的治疗策略的评估.
主要成果:
- 第一代和第二代BTKis在MCL中表现出更好的结果.
- 乙基基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因
- 对于TP53突变的MCL,建议采用非化疗方法.
结论:
- BTKis代表了地幔细胞淋巴瘤治疗的重大进步.
- 在第一线设置中优化BTKi的使用需要进一步的研究.
- 个性化治疗策略,特别是TP53突变的MCL,至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)